



Regd. Office 301, E – Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India.
Tel.: (+91 22) 2663 6450, Fax: (+91 22) 2610 8030, Email: info@nglfinechem.com CIN L24110MH1981PLC025884, Website www.nglfinechem.com

May 22, 2026

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400 001.

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No.C/1, G
Block, Bandra Kurla Complex, Bandra East,
Mumbai 400050.

Scrip Code: 524774

Symbol: NGLFINE

Sub: Investor Presentation – Q4 & FY 26.

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit Investors presentation – Q4 & FY 26.

The above presentation is also being made available on the Company's website at www.nglfinechem.com

You are requested to kindly take the information on record.

Thanking you,

Yours faithfully,

For NGL Fine-Chem Limited

Shivam Gharat
Company Secretary
M. No.: A56704

Encl: As above.

NGL Fine-Chem Limited

INVESTOR PRESENTATION



Q4 & FY26

Disclaimer

This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be deemed to constitute an offer. No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements", including those relating to the general business plans and strategy of NGL Fine-Chem Limited, its future financial condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements which contain words or phrases such as 'will', 'expected to', 'horizons of growth', 'strong growth prospects', etc., or similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. NGL Fine-Chem Limited may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner.

Inside This Presentation

Pg. No.

04

Q4 & FY26
Highlights

Pg. No.


10

Overview,
Key Strengths
and Strategy

Pg. No.

15

Historical
Financial
Performance



01

Q4 & FY26 Highlights

- 05 MANAGEMENT COMMENTARY
- 06 QUARTERLY OPERATIONAL METRICS
- 07 SUMMARY OF PROFIT AND LOSS STATEMENT
- 08 SUMMARY OF BALANCE SHEET
- 09 SUMMARY OF CASH FLOW STATEMENT



MANAGEMENT COMMENTARY



Rahul Nachane
MANAGING DIRECTOR

Dear Shareholders,

"Q4FY26 delivered strong performance, characterized by a sharp uptick in sales driven entirely by volume expansion. This marks our third consecutive quarter of robust volume growth, reinforcing our confidence that the business is firmly on a recovery path. Notably, this improvement was broad-based across our entire product portfolio and geographic markets.

Phase I of our ongoing capex programme is now contributing meaningfully to operations, and the higher volumes during the quarter were comfortably serviced within this expanded capacity. This gives us confidence in our ability to support future growth without compromising on execution or service levels.

The quarter was not without its challenges. Ongoing geopolitical volatility drove up freight costs and raw material prices. Because we were operating under fixed-price contracts, these cost escalations could not be immediately passed on to customers. The

movements in the forex markets lead to mark to market provisions further depressing the margins. In addition, shortages of gas and labour impacted the execution of our capex, resulting in some delay. Consequently, the commissioning of Phase II, earlier expected in Q1FY27, is now scheduled for early Q2FY27. However, we remain on track to commence commercial production from H2FY27 as planned.

On a positive note, we have been successful in partial price pass-through to customers in the first quarter, which should help restore margins going forward. Coupled with the strong volume momentum we are witnessing we expect this to support healthy performance in the coming quarters.

After three challenging years, the business is clearly back on a growth trajectory. We remain focused on disciplined execution of our strategy and are confident of delivering steady, sustainable growth in the years ahead."

Quarterly Operational Metrics

SEGMENTAL REVENUE MIX

PARTICULARS	Q4FY25	Q3FY26	Q4FY26
ANIMAL API	90%	92%	95%
HUMAN API	7%	2%	2%
INTERMEDIATES	1%	4%	1%
FORMULATIONS	2%	1%	1%

GEOGRAPHIC MIX

PARTICULARS	Q4FY25	Q3FY26	Q4FY26
Asia	37%	38%	43%
Europe	10%	8%	9%
India	27%	29%	23%
ROW	26%	25%	26%
USA	0%	0%	0%

PRODUCT CONCENTRATION

PARTICULARS	Q4FY25	Q3FY26	Q4FY26
TOP 3 PRODUCTS	33%	28%	29%
TOP 5 PRODUCTS	50%	44%	44%
TOP 10 PRODUCTS	72%	65%	66%

CUSTOMER CONCENTRATION

PARTICULARS	Q4FY25	Q3FY26	Q4FY26
TOP 3 CUSTOMERS	14%	12%	12%
TOP 5 CUSTOMERS	23%	17%	18%
TOP 10 CUSTOMERS	35%	29%	29%

Summary of Profit and Loss Statement

₹ IN CRORES

PARTICULARS	Q4FY25	Q3FY26	Q4FY26	Q-o-Q	Y-o-Y	FY25	FY26	Y-o-Y
REVENUE FROM OPERATIONS	94.97	127.51	149.23	17.04%	57.13%	368.26	500.95	36.03%
OTHER INCOME	-0.97	4.61	2.46	46.67%	-354.68%	8.63	14.73	70.65%
TOTAL INCOME	94.01	132.12	151.69	14.81%	61.36%	376.89	515.68	36.83%
TOTAL OPERATING EXPENSES	88.65	105.20	127.82	21.51%	44.18%	334.39	428.26	28.07%
EBITDA	6.32	22.31	21.41	-4.04%	238.81%	33.87	72.69	114.62%
EBITDA MARGIN (%)	6.65%	17.50%	14.35%	-315 bps	769 bps	9.20%	14.51%	531 bps
FINANCE COST	0.97	1.07	1.01	-6.24%	3.49%	2.33	4.47	91.40%
DEPRECIATION AND AMORTISATION EXPENSES	3.32	5.18	5.05	-2.50%	52.13%	12.45	19.58	57.28%
PROFIT BEFORE TAX	1.06	20.67	17.81	-13.82%	1,580.11%	27.71	63.37	128.65%
PROFIT AFTER TAX	0.54	15.69	13.49	-14.05%	2,380.79%	21.12	48.13	127.83%

Summary of Balance Sheet

₹ IN CRORES

PARTICULARS

SHAREHOLDERS FUND

NON CURRENT LIABILITIES

LONG TERM BORROWINGS

CURRENT LIABILITIES

SHORT TERM BORROWINGS

TOTAL EQUITY AND LIABILITIES

NON CURRENT ASSETS

NET BLOCK

CURRENT ASSETS

INVENTORIES

TRADE RECEIVABLES

CASH & BANK BALANCES

TOTAL ASSETS

FY25

FY26

282.43

329.23

31.99

66.25

25.34

56.40

118.97

150.01

48.00

52.02

433.39

545.50

198.01

269.11

142.12

164.09

235.38

276.39

51.27

70.28

82.84

130.88

4.97

5.11

433.39

545.50

Summary of Cash Flow Statement

₹ IN CRORES

PARTICULARS

FY25

FY26

CASH FLOW FROM OPERATING ACTIVITIES

32.36

43.32

CASH FLOW FROM INVESTING ACTIVITIES

(69.68)

(70.59)

CASH FLOW FROM FINANCING ACTIVITIES

37.46

29.55

NET CASH FLOW

0.14

2.27

CASH AT THE BEGINNING OF YEAR

0.40

0.53

CASH AT THE END OF YEAR

0.53

2.81

02

Overview, **Strengths and Strategy**

- 11 LEADING ANIMAL HEALTH COMPANY
- 12 LEADERSHIP IN VETERINARY API SEGMENT
- 13 STATE-OF-THE-ART MANUFACTURING CAPABILITIES
- 14 STRATEGY FOR NEXT LEG OF GROWTH



Leading Animal Health Company



COMPREHENSIVE PRODUCT PORTFOLIO

- 45 APIs (43 Veterinary APIs, 2 Human APIs), 1 Intermediates and 11 finished dosage forms
- Best quality and value-driven pricing



MARKET LEADERSHIP IN VETERINARY API

- Market leadership in our top products
- Growing position in next 4 – taking market share from other players



MANUFACTURING EXCELLENCE

- 3 state of the art manufacturing facilities
- Strong R&D capabilities in custom synthesis



LARGE GLOBAL PRESENCE

- Strong presence across the globe with country-wise regulatory approvals
- Strong presence in unregulated markets



LONG STANDING CUSTOMER RELATIONSHIPS

- ~451 customers
- Reliable supplier focused on good sale support to all customers

Leadership in Veterinary API Segment

Strong controls of processes with **95%** in-house manufacturing and backward integrated facilities leading to cost competitiveness


High quality and reliable products with no market rejection in **15 years**

Market share ranging from **15% to 50%+** in key products

Suppliers to **5 of top 10** global animal healthcare companies

REVENUE FROM VETERINARY API SEGMENT

(₹ IN CRORES)



13%
CAGR

WIDE RANGE OF PRODUCT CATEGORIES

ANTHELMINTICS

ECTOPARASITICIDES

ANTIPROTOZOALS

PHOSPHORUS SUPPLEMENTS

CUSTOMER & PRODUCT CONCENTRATION (OF SALES FY26)

	CUSTOMER	PRODUCT
TOP 3	10% (12% FY25)	28% (33% FY25)
TOP 5	15% (19% FY25)	45% (47% FY25)
TOP 10	26% (30% FY25)	65% (68% FY25)

State-of-the-art Manufacturing Capabilities



5 manufacturing facilities located at Tarapur & Navi Mumbai, Maharashtra, designed to meet the requirements of regulatory agencies and are capable of a wide range of reaction capabilities

75%

PRODUCTION COMING FROM ZERO LIQUID DISCHARGE FACILITIES

HIGHLIGHTS

20,000 m²

AREA OF MANUFACTURING FACILITIES

168 kl

GLASS-LINED REACTORS

253 kl

STAINLESS STEEL REACTORS

36 m³

GAS INDUCTION REACTORS

-20°C to +250°C

REACTION RANGE



ACCREDITATIONS

WHO-GMP, ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and cGMP accredited

Strategy for next leg of growth



**ONGOING INITIATIVES
TO INCREASE
CAPACITIES TO MEET
GROWING DEMAND**

BROWNFIELD EXPANSION

- Completed expansion in subsidiary Macrotech
- Additional capacities of intermediates
- Commercial production started



**LARGER EXPANSION
TO DRIVE THE NEXT
LEG OF EXPONENTIAL
GROWTH**

GREENFIELD EXPANSION AT TARAPUR

- Capacity expansion with sufficient capacity to meet demand for new products in pipeline
- Estimated capex of ₹ 210 Cr to be funded through debt and internal accrual
- Civil construction undergoing. Invested ₹ 182.75 crores till Q4FY26

03

Historical Financial **Performance**


16 ROBUST FINANCIAL PERFORMANCE



Robust Financial Performance


REVENUE

(₹ IN CRORES)




GROSS MARGIN

(IN %)




EBITDA

(₹ IN CRORES)




EBITDA MARGIN

(IN %)




PAT

(₹ IN CRORES)



PAT MARGIN

(IN %)



EBITDA excludes Other Income

Thank **You**

**FOR ANY FURTHER INFORMATION,
PLEASE CONTACT**

Shivam Gharat

NGL FINE-CHEM
LIMITED

cs@nglfinechem.com
+91 22 40842222

Abhishek Mehra

TIL ADVISORS PRIVATE
LIMITED

abhishek@theinvestmentlab.in
+91 95588 14500

 **NGL FINE-CHEM LIMITED**

Corporate Office

301, E-square, Subhash Road,
Vile Parle (East),
Mumbai - 400057,
Maharashtra, India

nglfinechem.com